Le Lézard
Classified in: Health
Subjects: CCA, FDA, FVT

Jazz Pharmaceuticals Announces Webcast for Vyxeos Investor Update



DUBLIN, Aug. 3, 2017 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will host a webcast on Monday, August 7, 2017 at 4:30 p.m. EDT/9:30 p.m. IST to provide investors with an update on Vyxeostm (daunorubicin and cytarabine) liposome for injection, which was approved by the U.S. Food and Drug Administration on August 3, 2017 for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC).

The webcast will include an overview of AML from invited physician experts as well as a Vyxeos overview from the company's senior management.

Interested parties may access the webcast via the Investors section of the Jazz Pharmaceuticals website at www.jazzpharmaceuticals.com.  Please connect to the website prior to the start of the webcast to ensure adequate time for any software downloads that may be necessary to listen to the webcast.

An archive of the webcast will be available for at least one week following the presentation on the Investors section of the company's website at www.jazzpharmaceuticals.com.

For further reference information on AML, including Vyxeos pricing considerations, please click here. For full prescribing information, please visit www.vyxeos.com.

About Jazz Pharmaceuticals
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) is an international biopharmaceutical company focused on improving patients' lives by identifying, developing and commercializing meaningful products that address unmet medical needs.  The company has a diverse portfolio of products and product candidates, with a focus in the areas of sleep and hematology/oncology.  In these areas, Jazz Pharmaceuticals markets Xyrem® (sodium oxybate) oral solution, Erwinaze® (asparaginase Erwinia chrysanthemi), Defitelio® (defibrotide sodium) and Vyxeostm (daunorubicin and cytarabine) liposome for injection in the U.S. and markets Erwinase® and Defitelio (defibrotide) in countries outside the U.S.  For more information, please visit www.jazzpharmaceuticals.com.

Jazz Pharmaceuticals Logo (PRNewsFoto/Jazz Pharmaceuticals plc)

 

Logo - http://mma.prnewswire.com/media/272253/Jazz_Pharmaceuticals_Logo.jpg 


These press releases may also interest you

at 02:00
LONDON, October 23, 2017 /PRNewswire/ --   Kx technology to support BrainWaveBank as it uses AI to transform cognitive health -   Solutions based on Kx will allow individuals to monitor their cognitive health and allow BrainWaveBank to develop...

at 01:43
OSLO, Norway, Oct. 23, 2017 /PRNewswire/ -- Nordic Nanovector ASA (OSE: NANO) announces the following presentations by the company's research collaborators at the European Association of Nuclear Medicine annual meeting (EANM; 21-25 October; Vienna,...

at 01:00
LEIDEN, The Netherlands, October 23, 2017 /PRNewswire/ -- Net result is a reduction of the fully diluted share capital by 8,212,468 shares  Total number of shares issued in warrant exercises, option exercises and bond conversions since the...

at 00:01
VANCOUVER, Oct 23, 2017 /CNW/ - More than 2,500 heart health experts from across Canada and around the globe meet again in Vancouver today for the Canadian Cardiovascular Congress. Experts at all stages of their careers collaborate, share new ideas,...

22 oct 2017
LAGUNA NIGUEL, Calif., Oct. 22, 2017 /PRNewswire/ -- The management team of Crestavilla, a luxury senior living community currently under construction in Laguna Niguel, Calif., has launched a Halloween costume drive to benefit the boys and girls who...

22 oct 2017
OTTAWA, Oct. 20, 2017 /CNW/ - The Honourable Ginette Petitpas Taylor, Minister of Health, will deliver remarks at the Kid Food Nation Gala and present awards to the winners of the national recipe contest. The Minister will be available to answer...




News published on 3 august 2017 at 10:15 and distributed by: